Cargando…
From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial
INTRODUCTION: A variety of radiolabelled minigastrin analogues targeting the cholecystokinin 2 (CCK2) receptor were developed and compared in a concerted preclinical testing to select the most promising radiotracer for diagnosis and treatment of medullary thyroid carcinoma (MTC). DOTA–DGlu–DGlu–DGlu...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817208/ https://www.ncbi.nlm.nih.gov/pubmed/26826279 http://dx.doi.org/10.1016/j.ejps.2016.01.023 |
_version_ | 1782424857156255744 |
---|---|
author | Pawlak, Dariusz Rangger, Christine Peitl, Petra Kolenc Garnuszek, Piotr Maurin, Michał Ihli, Laura Kroselj, Marko Maina, Theodosia Maecke, Helmut Erba, Paola Kremser, Leopold Hubalewska-Dydejczyk, Alicja Mikołajczak, Renata Decristoforo, Clemens |
author_facet | Pawlak, Dariusz Rangger, Christine Peitl, Petra Kolenc Garnuszek, Piotr Maurin, Michał Ihli, Laura Kroselj, Marko Maina, Theodosia Maecke, Helmut Erba, Paola Kremser, Leopold Hubalewska-Dydejczyk, Alicja Mikołajczak, Renata Decristoforo, Clemens |
author_sort | Pawlak, Dariusz |
collection | PubMed |
description | INTRODUCTION: A variety of radiolabelled minigastrin analogues targeting the cholecystokinin 2 (CCK2) receptor were developed and compared in a concerted preclinical testing to select the most promising radiotracer for diagnosis and treatment of medullary thyroid carcinoma (MTC). DOTA–DGlu–DGlu–DGlu–DGlu–DGlu–DGlu– Ala–Tyr–Gly–Trp–Met–Asp–Phe–NH(2) (CP04) after labelling with (111)In displayed excellent characteristics, such as high stability, receptor affinity, specific and persistent tumour uptake and low kidney retention in animal models. Therefore, it was selected for further clinical evaluation within the ERA-NET project GRAN-T-MTC. Here we report on the development of a pharmaceutical freeze-dried formulation of the precursor CP04 for a first multi-centre clinical trial with (111)In-CP04 in MTC patients. MATERIALS AND METHODS: The kit formulation was optimised by adjustment of buffer, additives and radiolabelling conditions. Three clinical grade batches of a final kit formulation with two different amounts of peptide (10 or 50 μg) were prepared and radiolabelled with (111)In. Quality control and stability assays of both the kits and the resulting radiolabelled compound were performed by HPLC analysis. RESULTS: Use of ascorbic acid buffer (pH 4.5) allowed freeze-drying of the kit formulation with satisfactory pellet-formation. Addition of methionine and gentisic acid as well as careful selection of radiolabelling temperature was required to avoid extensive oxidation of the Met(11)-residue. Trace metal contamination, in particular Zn, was found to be a major challenge during the pharmaceutical filling process in particular for the 10 μg formulation. The final formulations contained 10 or 50 μg CP04, 25 mg ascorbic acid, 0.5 mg gentisic acid and 5 mg l-methionine. The radiolabelling performed by incubation of 200–250 MBq (111)InCl(3) at 90 °C for 15 min resulted in reproducible radiochemical purity (RCP) >94%. Kit-stability was proven for >6 months at +5 °C and at +25 °C. The radiolabelled product was stable for >4 h at +25 °C. CONCLUSION: A kit formulation to prepare (111)In-CP04 for clinical application was developed, showing high stability of the kit as well as high RCP of the final product. |
format | Online Article Text |
id | pubmed-4817208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-48172082016-04-01 From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial Pawlak, Dariusz Rangger, Christine Peitl, Petra Kolenc Garnuszek, Piotr Maurin, Michał Ihli, Laura Kroselj, Marko Maina, Theodosia Maecke, Helmut Erba, Paola Kremser, Leopold Hubalewska-Dydejczyk, Alicja Mikołajczak, Renata Decristoforo, Clemens Eur J Pharm Sci Article INTRODUCTION: A variety of radiolabelled minigastrin analogues targeting the cholecystokinin 2 (CCK2) receptor were developed and compared in a concerted preclinical testing to select the most promising radiotracer for diagnosis and treatment of medullary thyroid carcinoma (MTC). DOTA–DGlu–DGlu–DGlu–DGlu–DGlu–DGlu– Ala–Tyr–Gly–Trp–Met–Asp–Phe–NH(2) (CP04) after labelling with (111)In displayed excellent characteristics, such as high stability, receptor affinity, specific and persistent tumour uptake and low kidney retention in animal models. Therefore, it was selected for further clinical evaluation within the ERA-NET project GRAN-T-MTC. Here we report on the development of a pharmaceutical freeze-dried formulation of the precursor CP04 for a first multi-centre clinical trial with (111)In-CP04 in MTC patients. MATERIALS AND METHODS: The kit formulation was optimised by adjustment of buffer, additives and radiolabelling conditions. Three clinical grade batches of a final kit formulation with two different amounts of peptide (10 or 50 μg) were prepared and radiolabelled with (111)In. Quality control and stability assays of both the kits and the resulting radiolabelled compound were performed by HPLC analysis. RESULTS: Use of ascorbic acid buffer (pH 4.5) allowed freeze-drying of the kit formulation with satisfactory pellet-formation. Addition of methionine and gentisic acid as well as careful selection of radiolabelling temperature was required to avoid extensive oxidation of the Met(11)-residue. Trace metal contamination, in particular Zn, was found to be a major challenge during the pharmaceutical filling process in particular for the 10 μg formulation. The final formulations contained 10 or 50 μg CP04, 25 mg ascorbic acid, 0.5 mg gentisic acid and 5 mg l-methionine. The radiolabelling performed by incubation of 200–250 MBq (111)InCl(3) at 90 °C for 15 min resulted in reproducible radiochemical purity (RCP) >94%. Kit-stability was proven for >6 months at +5 °C and at +25 °C. The radiolabelled product was stable for >4 h at +25 °C. CONCLUSION: A kit formulation to prepare (111)In-CP04 for clinical application was developed, showing high stability of the kit as well as high RCP of the final product. 2016-01-27 2016-03-31 /pmc/articles/PMC4817208/ /pubmed/26826279 http://dx.doi.org/10.1016/j.ejps.2016.01.023 Text en This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pawlak, Dariusz Rangger, Christine Peitl, Petra Kolenc Garnuszek, Piotr Maurin, Michał Ihli, Laura Kroselj, Marko Maina, Theodosia Maecke, Helmut Erba, Paola Kremser, Leopold Hubalewska-Dydejczyk, Alicja Mikołajczak, Renata Decristoforo, Clemens From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial |
title | From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial |
title_full | From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial |
title_fullStr | From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial |
title_full_unstemmed | From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial |
title_short | From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial |
title_sort | from preclinical development to clinical application: kit formulation for radiolabelling the minigastrin analogue cp04 with in-111 for a first-in-human clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817208/ https://www.ncbi.nlm.nih.gov/pubmed/26826279 http://dx.doi.org/10.1016/j.ejps.2016.01.023 |
work_keys_str_mv | AT pawlakdariusz frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT ranggerchristine frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT peitlpetrakolenc frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT garnuszekpiotr frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT maurinmichał frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT ihlilaura frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT kroseljmarko frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT mainatheodosia frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT maeckehelmut frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT erbapaola frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT kremserleopold frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT hubalewskadydejczykalicja frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT mikołajczakrenata frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial AT decristoforoclemens frompreclinicaldevelopmenttoclinicalapplicationkitformulationforradiolabellingtheminigastrinanaloguecp04within111forafirstinhumanclinicaltrial |